Randomized, double-blind and phase II CITYSCAPE trial (NCT03563716), which evaluated the efficacy and safety of the anti-TIGIT monoclonal antibody tiragolumab plus the anti-PD-L1 atezolizumab compared with atezolizumab alone as a first-line treatment for patients with PD-L1-positive NSCLC, showed a clinical benefit on the overall response rate (37% versus placebo 21%) and progression-free survival (5.5 months versus placebo 3.88 months) (98). Here, CD274 is linked to non-small cell lung carcinoma.